HIV/AIDS Therapy

Pharmacokinetics study results presented on once-daily HIV combination therapy

Published in AIDS Weekly, August 22nd, 2005

An open label, single-arm study conducted among 15 HIV-positive patients evaluated the pharmacokinetic parameters of a once-daily combination of Lexiva (fosamprenavir calcium), ritonavir and Truvada (tenofovir and emtricitabine) after 4 weeks of treatment.

Results showed that plasma levels of all 4 drugs remained within previously described pharmacokinetic parameters, supporting the potential for this combination to be a useful once-daily regimen for the treatment of HIV infection. However, further study is necessary to determine conclusively the safety and efficacy of Lexiva/ritonavir in combination with Truvada.

The study, which was supported by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry